These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38388794)

  • 1. Clinical implications of additional chromosomal abnormalities in adult acute myeloid leukemia with inv (16)/t(16;16)/CBFB::MYH11.
    Gao J; Santana-Santos L; Fu L; Alvey E; Chen Q; Wolniak K; Xia Z; Aqil B; Behdad A; Ji P; Sukhanova M; Abaza Y; Altman JK; Chen YH; Lu X
    Eur J Haematol; 2024 Jun; 112(6):964-974. PubMed ID: 38388794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3'CBFB deletion in CBFB-rearranged acute myeloid leukemia retains morphological features associated with inv(16), but patients have higher risk of relapse and may require stem cell transplant.
    Tang G; Zou Y; Wang SA; Borthakur G; Toruner G; Hu S; Li S; Xu J; Medeiros LJ; Tang Z
    Ann Hematol; 2022 Apr; 101(4):847-854. PubMed ID: 35184217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rare CBFB-MYH11 fusion transcripts in AML with inv(16)/t(16;16) are associated with therapy-related AML M4eo, atypical cytomorphology, atypical immunophenotype, atypical additional chromosomal rearrangements and low white blood cell count: a study on 162 patients.
    Schnittger S; Bacher U; Haferlach C; Kern W; Haferlach T
    Leukemia; 2007 Apr; 21(4):725-31. PubMed ID: 17287858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute myeloid leukemia with inv(16) with CBFB-MYH11, 3'CBFB deletion, variant t(9;22) with BCR-ABL1, and del(7)(q22q32) in a pediatric patient: case report and literature review.
    Tirado CA; Valdez F; Klesse L; Karandikar NJ; Uddin N; Arbini A; Fustino N; Collins R; Patel S; Smart RL; Garcia R; Doolittle J; Chen W
    Cancer Genet Cytogenet; 2010 Jul; 200(1):54-9. PubMed ID: 20513535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Jumping translocation involving chromosome 13q in a patient with Crohn's Disease and inv(16)(p13.1q22)/CBFB-MYH11 acute myeloid leukemia.
    Clarke S; de Kraa R; Chuah H; Creeper K; Leahy MF; Wright M
    Cancer Genet; 2022 Aug; 266-267():7-14. PubMed ID: 35613501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Most Myeloid Neoplasms With Deletion of Chromosome 16q Are Distinct From Acute Myeloid Leukemia With Inv(16)(p13.1q22): A Bone Marrow Pathology Group Multicenter Study.
    Rogers HJ; Hsi ED; Tang G; Wang SA; Bueso-Ramos CE; Lubin D; Morrissette JJ; Bagg A; Cherukuri DP; George TI; Peterson L; Liu YC; Mathew S; Orazi A; Hasserjian RP
    Am J Clin Pathol; 2017 Apr; 147(4):411-419. PubMed ID: 28375434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute myeloid leukemia with t(16;16) (p13;q22) showing a new CBFB-MYH11 fusion transcript associated with an atypical leukemic blasts morphology.
    Albano F; Anelli L; Zagaria A; Coccaro N; Tota G; Impera L; Minervini CF; Cellamare A; Delia M; Minervini A; Casieri P; Specchia G
    Hum Pathol; 2014 Mar; 45(3):643-7. PubMed ID: 24342433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of a novel CBFB-MYH11 fusion transcript in acute myeloid leukemia M1 with inv(16)(p13q22).
    Kurata K; Yamamoto K; Okazaki Y; Noguchi Y; Matsui K; Matsumoto H; Inui Y; Yakushijin K; Ito M; Nakamachi Y; Matsuoka H; Saegusa J; Minami H
    Cancer Genet; 2020 Feb; 241():72-76. PubMed ID: 31353165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gata2 deficiency delays leukemogenesis while contributing to aggressive leukemia phenotype in Cbfb-MYH11 knockin mice.
    Saida S; Zhen T; Kim E; Yu K; Lopez G; McReynolds LJ; Liu PP
    Leukemia; 2020 Mar; 34(3):759-770. PubMed ID: 31624376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inversion and deletion of 16q22 defined by array CGH, FISH, and RT-PCR in a patient with AML.
    Dawson AJ; Bal S; McTavish B; Tomiuk M; Schroedter I; Ahsanuddin AN; Seftel MD; Vallente R; Mai S; Cotter PD; Hovanes K; Gorre M; Gunn SR
    Cancer Genet; 2011 Jun; 204(6):344-7. PubMed ID: 21763633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of CBFB/MYH11 transcripts in patients with inversion and other abnormalities of chromosome 16 at presentation and remission.
    Tobal K; Johnson PR; Saunders MJ; Harrison CJ; Liu Yin JA
    Br J Haematol; 1995 Sep; 91(1):104-8. PubMed ID: 7577615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors?
    Dissing M; Le Beau MM; Pedersen-Bjergaard J
    J Clin Oncol; 1998 May; 16(5):1890-6. PubMed ID: 9586906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute myeloid leukemia with cryptic CBFB-MYH11 type D.
    Kobayashi T; Ichikawa M; Kamikubo Y; Kurokawa M
    Int J Clin Exp Pathol; 2013; 6(1):110-2. PubMed ID: 23236551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection and quantification of CBFB/MYH11 fusion transcripts in patients with inv(16)-positive acute myeloblastic leukemia by real-time RT-PCR.
    Krauter J; Hoellge W; Wattjes MP; Nagel S; Heidenreich O; Bunjes D; Ganser A; Heil G
    Genes Chromosomes Cancer; 2001 Apr; 30(4):342-8. PubMed ID: 11241787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization and use of an antibody detecting the CBFbeta-SMMHC fusion protein in inv(16)/t(16;16)-associated acute myeloid leukemias.
    Viswanatha DS; Chen I; Liu PP; Slovak ML; Rankin C; Head DR; Willman CL
    Blood; 1998 Mar; 91(6):1882-90. PubMed ID: 9490670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AML with inv(16)/t(16;16) and high-risk cytogenetic abnormalities: atypical features and unfavorable outcome.
    Assaf N; Lefebvre C; Raggueneau V; Guignedoux G; Marceau-Renaut A; Chevalier S; Tondeur S; Bories D; Benramdane R; Rousselot P; Terré C
    Hematology; 2022 Dec; 27(1):636-641. PubMed ID: 35622005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of the CBFB/MYH11 fusion gene in de novo acute myeloid leukemia (AML): a single-institution study of 224 Japanese AML patients.
    Monma F; Nishii K; Shiga J; Sugahara H; Lorenzo F; Watanabe Y; Kawakami K; Hosokai N; Yamamori S; Katayama N; Shiku H
    Leuk Res; 2007 Apr; 31(4):471-6. PubMed ID: 17052753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The loss or absence of minimal residual disease of <0·1% at any time after two cycles of consolidation chemotherapy in CBFB-MYH11-positive acute myeloid leukaemia indicates poor prognosis.
    Duan W; Liu X; Jia J; Wang J; Gong L; Jiang Q; Zhao T; Wang Y; Zhang X; Xu L; Zhao X; Qin Y; Shi H; Chang Y; Huang X; Jiang H
    Br J Haematol; 2021 Jan; 192(2):265-271. PubMed ID: 32588434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RT-PCR diagnosis of patients with acute nonlymphocytic leukemia and inv(16)(p13q22) and identification of new alternative splicing in CBFB-MYH11 transcripts.
    van der Reijden BA; Lombardo M; Dauwerse HG; Giles RH; Mühlematter D; Bellomo MJ; Wessels HW; Beverstock GC; van Ommen GJ; Hagemeijer A
    Blood; 1995 Jul; 86(1):277-82. PubMed ID: 7795233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CBFB-MYH11 fusion neoantigen enables T cell recognition and killing of acute myeloid leukemia.
    Biernacki MA; Foster KA; Woodward KB; Coon ME; Cummings C; Cunningham TM; Dossa RG; Brault M; Stokke J; Olsen TM; Gardner K; Estey E; Meshinchi S; Rongvaux A; Bleakley M
    J Clin Invest; 2020 Oct; 130(10):5127-5141. PubMed ID: 32831296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.